London, UK, Friday 30 May 2025 – Today, AstraZeneca announced that the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga ...

AstraZeneca’s UK president, Tom Keith-Roach, said: “We are delighted by NICE’s decision to broaden access to dapagliflozin for patients with CKD. CKD places significant burden on patients, their ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use. An estimated 7.2 million people in the UK are living with the progressive condition. AstraZeneca (AZ) has announced that ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), ... AZ's SGLT2 inhibitor Farxiga/Forxiga (dapagliflozin) ...

Objective To assess the efficacy and safety of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with metabolic dysfunction-associated steatohepatitis (MASH). Design ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceutical with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases.. The Friday ...

MASH resolution without worsening of fibrosis occurred in 23% of those on dapagliflozin and 8% of those on placebo (RR 2.91, 95% CI 1.22-6.97, P=0.01), while fibrosis improvement by at least one ...

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on limiting prescription drug prices goes against a federal program.

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments. Based in ...